HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Caffeine enhances the antidepressant-like activity of common antidepressant drugs in the forced swim test in mice.

Abstract
Caffeine is the most widely used behaviorally active drug in the world which exerts its activity on central nervous system through adenosine receptors. Worrying data indicate that excessive caffeine intake applies to patients suffering from mental disorders, including depression. The main goal of the present study was to evaluate the influence of caffeine on animals' behavior in forced swim test (FST) as well as the effect of caffeine (5 mg/kg) on the activity of six typical antidepressants, such as imipramine (15 mg/kg), desipramine (10 mg/kg), fluoxetine (5 mg/kg), paroxetine (0.5 mg/kg), escitalopram (2 mg/kg), and reboxetine (2.5 mg/kg). Locomotor activity was estimated to verify and exclude false-positive/negative results. In order to assess the influence of caffeine on the levels of antidepressant drugs studied, their concentrations were determined in murine serum and brains using high-performance liquid chromatography. The results showed that caffeine at a dose of 10, 20, and 50 mg/kg exhibited antidepressant activity in the FST, and it was not related to changes in locomotor activity in the animals. Caffeine at a dose of 5 mg/kg potentiated the activity of all antidepressants, and the observed effects were not due to the increase in locomotor activity in the animals. The interactions between caffeine and desipramine, fluoxetine, escitalopram, and reboxetine were exclusively of pharmacodynamic character, because caffeine did not cause any changes in the concentrations of these drugs neither in blood serum nor in brain tissue. As a result of joint administration of caffeine and paroxetine, an increase in the antidepressant drug concentrations in serum was observed. No such change was noticed in the brain tissue. A decrease in the antidepressant drug concentrations in brain was observed in the case of imipramine administered together with caffeine. Therefore, it can be assumed that the interactions caffeine-paroxetine and caffeine-imipramine occur at least in part in the pharmacokinetic phase.
AuthorsAleksandra Szopa, Ewa Poleszak, Elżbieta Wyska, Anna Serefko, Sylwia Wośko, Aleksandra Wlaź, Mateusz Pieróg, Andrzej Wróbel, Piotr Wlaź
JournalNaunyn-Schmiedeberg's archives of pharmacology (Naunyn Schmiedebergs Arch Pharmacol) Vol. 389 Issue 2 Pg. 211-21 (Feb 2016) ISSN: 1432-1912 [Electronic] Germany
PMID26614569 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References
  • Antidepressive Agents
  • Caffeine
Topics
  • Animals
  • Antidepressive Agents (blood, pharmacokinetics, pharmacology)
  • Behavior, Animal (drug effects)
  • Brain (metabolism)
  • Caffeine (pharmacology)
  • Chromatography, High Pressure Liquid
  • Depression (blood, drug therapy, psychology)
  • Disease Models, Animal
  • Drug Interactions
  • Male
  • Mice
  • Motor Activity (drug effects)
  • Swimming

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: